
Swissmedic Authorises CSL’s HEMGENIX®as First Gene Therapy for Hemophilia B
Global biotechnology leader CSL (ASX: CSL) today announced that Swissmedic has authorised HEMGENIX® (etranacogene dezaparvovec), the first and currently only gene therapy for the treatment of male adults aged >18 years with…











